Trial site
Rigas 1. slimnica SIA
- 10running trials
- 12closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- Psoriasis6 trials
- Bronchiectasis3 trials
- Psoriatic arthritis3 trials
- Asthma2 trials
- Atopic dermatitis (eczema)2 trials
- Atrial fibrillation2 trials
- COPD2 trials
- Heart failure2 trials
- Familial hypercholesterolaemia1 trial
- Stroke1 trial
- Phase
- Phase 318 trials
- Phase 23 trials
- Phase 41 trial
- Status
- Completed12 trials
- Active, not recruiting6 trials
- Not yet recruiting2 trials
- Recruiting2 trials
- Lead sponsor
- Boehringer Ingelheim3 trials
- Chiesi Farmaceutici S.p.A.3 trials
- Takeda3 trials
- Alumis Inc2 trials
- MoonLake Immunotherapeutics AG2 trials
- and 9 more
Running trials
Not yet recruiting
Not yet recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Active, not recruiting
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Atrial fibrillation1 recruiting
- Bronchiectasis1 recruiting
- Heart failure1 recruiting
- Psoriatic arthritis1 recruiting
Closed trials
Recruiting
Completed
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Completed
Completed
Completed
Completed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Completed
Completed
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
Completed
Completed
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy
Completed
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Site data: EU CTIS (euclinicaltrials.eu)Updated 13 Nov 2026